sector medic suppli devic
 strong rise cgm penetr
messag revenu yoy came
consensu driven second straight quarter strong sale improv
momentum impress consid success abbott ad patient
quarter suggest us ramp cgm adopt may near-term least
rise tide lift boat even competit intensifi remain concern
share price evolv long-term expect question
take back seat investor focu shift instead upcom launch
 busi show ill effect increas competit
sale top street expect mark compani second
consecut quarter growth domest materi acceler gain
first three quarter meanwhil intern segment also
strong revenu top street estim adjust
currenc estim ou sale grew product level sensor sale
came consensu meanwhil hardwar revenu also
contribut beat transmitt receiv
top street expect respect
innov appear drive inflect cgm adopt talk
recent initi report see believ cgm market enter
disrupt phase spur rapid influx new technolog believ
disrupt could eventu result share shift price pressur neg impact
incumb player also potenti drive posit inflect cgm
penetr move closer standard care statu deserv view
insulin-depend patient result indic process appear
play estim abbott combin add nearli patient
collect instal base first quarter put context think
market grew patient overal libr continu demonstr
solid momentum slate full launch june new product
like enter market next month well
innov piec equat remain place balanc
focu go forward track full commerci
launch june ada manag note posit feedback patient limit
commerci experi date redesign push-button sensor applic
particular earn high mark addit high profil featur price
manag indic intern model assum sensor asp line
would impli reduct cost per day support base
label sensor life vice-president strategi corp dev steve pacelli emphas
mere assumpt compani unilater give price
contract discuss howev mani patient stretch use life
sensor day beyond think final asp close level like
outcom avoid would otherwis de facto per day price increas
meanwhil continu make progress number pipelin
initi japanes approv older system expect later quarter
although expect market develop slowli reimburs evolv
enhanc platform also work includ sensor life
next-gen transmitt cheaper produc long-term
verili product valid test compani continu make progress
highli anticip devic despit potenti new icgm design
eventu shorten develop time howev ceo kevin sayer retic pull
forward compani previous commun approv timelin product
respect stage continu page
page analyst certif import disclosur
incom statement higher expect sg one-tim gm
headwind larg off-set top line upsid report gross margin
yoy consensu call manag call
three factor neg impact margin one-tim inventori obsolesc
charg relat old receiv neg mix due faster growth ou
medicar popul revenu deferr associ upgrad program
adjust item gross margin would come closer elsewher
sg expens rose yoy sale well north street
estim final spend declin yoy revenu
consensu combin drove oper loss vs street
loss forecast made line favor interest/oth incom
brought net loss per share vs consensu expect loss
per share loss
guidanc move higher back strong perform manag rais
guidanc call revenu vs
previous howev compani endors consensu outlook come
wednesday print second quarter patient add expect
neg impact patient wait wide avail full year gross
margin still expect come oper expens peg
yoy exclud spend compani nascent non-intens program
long-term concern go away push back burner
model call post net loss per share total
revenu compar prior forecast net loss
per share sale also take out-year
estim larg faster assum cgm market penetr howev view
compani top line growth profil remain rel unchang
forecast could prove conserv underli cgm market growth exceed
expect competitor fail make signific inroad share perspect
also see increment downsid risk particularli price side model
modest pressur time see crosscurr fairli well
balanc result maintain neutral rate
page analyst certif import disclosur
leader develop continu glucos monitor cgm
technolog aid treatment manag diabet compani launch
first cgm system sixth gener cgm technolog
last twelv year time led way cgm grown
world-wide market posit impact live countless diabet patient
go forward believ cgm pois becom standard care insulin-
depend diabet nearli year sinc introduct countless studi
valid advantag cgm tradit point in-tim blood glucos test
reduc critic factor manag diabet yet despit compel
clinic evid support use penetr remain rel low today
 type popul less insulin-intens type patient
mani factor contribut lacklust adopt view includ inconsist
sensor accuraci conveni qualiti life issu high increment cost
therapi recent advanc address mani histor drawback
technolog pave way increas penetr
bullish outlook cgm adopt abil sustain
leadership posit market time believ field enter disrupt
phase spur rapid influx new technolog feedback physician
patient survey suggest could risk share price
perspect process play someth believ fulli reflect
stock current level result prefer wait better entri point
valu primarili ev/sal basi use repres group smid-
cap med-tech name similar growth characterist comp base guggenheim
factset consensu estim group current trade ntm sale line
multipl see valuat full limit visibl
rapidli evolv cgm competit landscap impact compani busi
next month assign share neutral rate
upsid risk rate includ cgm penetr ramp faster expect
lacklust adopt competit product new product approv improv
competit type popul and/or open type opportun
downsid risk rate includ faster expect adopt competit cgm
technolog price pressur reduc sale profit
develop novel diabet treatment could reduc need insulin dose
blood glucos measur
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
